Home
This Title All WIREs
WIREs RSS Feed
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 9.182

Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Cancer immunotherapy, or the utilization of a patient's own immune system to treat cancer, has shifted the paradigm of cancer treatment. Despite meaningful responses being observed in multiple studies, currently available immunotherapy platforms have only proven effective to a small subset of patients. To address this, nanoparticles have been utilized as a novel carrier for immunotherapeutic drugs, achieving robust anti‐tumor effects with increased adaptive and durable responses. Specifically, dendrimer nanoparticles have attracted a great deal of scientific interest due to their versatility in various therapeutic applications, resulting from their unique physicochemical properties and chemically well‐defined architecture. This review offers a comprehensive overview of dendrimer‐based immunotherapy technologies, including their formulations, biological functionalities, and therapeutic applications. Common formulations include: (1) modulators of cytokine secretion of immune cells (adjuvants); (2) facilitators of the recognition of tumorous antigens (vaccines); (3) stimulators of immune effectors to selectively attack cells expressing specific antigens (antibodies); and (4) inhibitors of immune‐suppressive responses (immune checkpoint inhibitors). On‐going works and prospects of dendrimer‐based immunotherapies are also discussed. Overall, this review provides a critical overview on rapidly growing dendrimer‐based immunotherapy technologies and serves as a guideline for researchers and clinicians who are interested in this field. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies
Schematic illustration of a dendrimer structure with examples of common types utilized for various applications
[ Normal View | Magnified View ]
Schematic illustration of the dendrimer–immune checkpoint inhibitor conjugates. (a) Immune checkpoint molecules for cancer immunotherapy. The thickness of arrows is proportional to the reported binding affinities between the molecules. (b) Enhanced PD‐1/PD‐L1 blockade due to the integration of aPD‐L1 antibodies to dendrimers. Reprinted from Bu, Nair, Iida et al. (2020). (c) The conjugation of PD‐1 derived peptide to dendrimers for PD‐L1 blockade. Reprinted from Jeong et al. (2020)
[ Normal View | Magnified View ]
Schematic illustration of the dendrimer–monoclonal antibody (mAb) conjugates. (a) mAb‐mediated immune cell functional assays. (b) Design and formulation of the dendrimer–mAb conjugates
[ Normal View | Magnified View ]
Components of dendrimer‐based vaccines. Vaccine platforms can be paired with several types of dendrimers, including polyamidoamine (PAMAM), multiple antigen peptide (MAP), and glycodendrimers, which can target multiple antigens. These systems offer the possibility of improving the bioavailability and pharmacokinetic properties of immunotherapeutic vaccines
[ Normal View | Magnified View ]
Schematic representation of the mechanism of immunogene therapy by lipid‐dendrimer NPs containing siRNA against the immune checkpoint PD‐L1 and pDNA encoding the immunostimulating cytokine IL‐2. Reprinted from K.‐W. Huang et al. (2020)
[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Emerging Technologies
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts